Search Clinical Trials in the EU

Duration

11-15 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

181-200 of 306 trials

Generalized Myasthenia Gravis: DNTH103 Treatment Study

We are testing a new treatment called DNTH103 for adults with generalized myasthenia gravis. The study aims to evaluate its safety, tolerability, and effectiveness in managing symptoms.

Myasthenia Gravis3-6 monthsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational MedicinesNeurology

Advanced Cancers with BRAF Mutations: Sorafenib and Trametinib Study

We are testing a combination of two medications for patients with advanced-stage cancers that have BRAF mutations. The goal is to find the best dose and understand how well this treatment works and its safety.

Advanced-Stage Cancer with BRAF Mutation>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits No Placebo Investigational MedicinesOncology

Major Depression: Samyr Injection Study

We are testing whether Samyr, an injectable treatment, can improve symptoms in people with major depression who are not responding well to their current antidepressants. This study compares Samyr to a placebo to assess its effectiveness and safety.

Major Depression Disorder≤3 monthsConfirmation phase (III)11-15 visits Investigational MedicinesPsychiatry

Psoriatic Arthritis: Zasocitinib Study

We are testing a new medication, Zasocitinib, for people with active psoriatic arthritis to see if it improves symptoms better than a placebo. The study also looks at how it affects daily life and physical function.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementRheumatology

Vertebral Metastases: Zoledronic Acid or Denosumab with Radiation

We are studying whether adding zoledronic acid or denosumab to stereotactic radiotherapy improves treatment outcomes for patients with vertebral metastases. This trial will also look at cost-effectiveness and various health impacts.

Metastatic Bone Pain>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesOncology

Hidradenitis Suppurativa: Remibrutinib Study

We are testing the effectiveness and safety of remibrutinib in adults with moderate to severe hidradenitis suppurativa. The study aims to see if it helps reduce symptoms like flare-ups and skin pain compared to a placebo.

Hidradenitis Suppurativa1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteAllergologyDermatology

KCNT1-Related Epilepsy: S230815 Treatment Study

We are testing a new treatment for children with KCNT1-related Developmental and Epileptic Encephalopathy. The study aims to evaluate its safety and how it may help reduce seizure activity.

KCNT1-related Developmental and Epileptic Encephalopathy1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Recurrent Meningioma: [177Lu]Lu-DOTATATE Treatment Study

We are investigating whether [177Lu]Lu-DOTATATE can effectively treat recurrent meningioma compared to standard care. The study will also look at safety and quality of life for participants.

Meningioma>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesNeurologyOncology

Frozen Embryo Transfer: The Role of Corpus Luteum

We are studying how the presence of the corpus luteum affects pregnancies from frozen embryo transfers. This research may help us understand its impact on maternal and fetal health.

Infertility6-12 monthsMonitoring phase (IV)11-15 visits No Placebo Standard MedicinesGynecology and Obstetrics

Immunotherapy for Advanced Cancer: Standard vs. Reduced Dose

We are comparing standard immunotherapy treatment with a less frequent dosing schedule for patients with advanced cancer. The goal is to see if the reduced dose is just as effective and to evaluate its impact on quality of life and safety.

Advanced or Metastatic Cancer>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesOncology

Breast Cancer Prevention: Denosumab for Women with BRCA1 Mutation

We are studying whether Denosumab can help prevent breast cancer in women carrying a BRCA1 mutation. This trial compares its effects to a placebo to see if it reduces cancer risk.

Breast Cancer Prevention in BRCA1 Mutation Carriers>2 yearsConfirmation phase (III)11-15 visits Standard Medicines Partially RemoteHematologyOncology

TBR1-Related Neurocognitive Disorder: Lithium Carbonate Study

We are studying whether lithium carbonate can improve behavior and communication in patients with TBR1-related neurocognitive disorder. This trial will also assess the treatment's safety and overall impact on quality of life.

TBR1 Variant>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteNeurologyPsychiatry

Sacituzumab Govitecan with Bevacizumab for Brain Metastases in Lung Cancer

We are studying a combination of two medications for patients with brain metastases from non-small cell lung cancer. The goal is to see how well this treatment works in reducing tumor size and improving patient outcomes.

Lung Cancer6-12 monthsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementNeurologyOncology

Advanced Melanoma: Regorafenib Treatment Study

We are studying the effects of regorafenib in patients with advanced melanoma who have already been treated. The goal is to see if it helps control the disease better when combined with other therapies.

Advanced Melanoma>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesDermatologyOncology

ANCA-Associated Vasculitis: Prednisone Treatment Study

We are investigating whether continuing low-dose prednisone helps maintain remission in patients with ANCA-associated vasculitis compared to stopping it after one month. This study will also look at potential side effects and relapse rates over time.

Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis>2 yearsConfirmation phase (III)11-15 visits Investigational MedicinesRheumatology

Actinic Keratosis: 5% Potassium Hydroxide Solution

We are studying whether a 5% potassium hydroxide solution is more effective than a placebo for treating mild to moderate actinic keratosis. The trial also looks at the safety of this treatment.

Actinic Keratosis3-6 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational MedicinesDermatology

Pulmonary Hypertension: TX000045 Treatment Study

We are testing a new medication, TX000045, for patients with pulmonary hypertension due to heart failure. The goal is to see if it improves heart function and is safe for use.

Pulmonary Hypertension3-6 monthsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Systemic Lupus Erythematosus: Cenerimod Study

We are examining the long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus. This study looks at how the medication works alongside existing treatments.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineRheumatology

Diabetic Macular Edema: Dexamethasone Implant Study

We are investigating a new treatment using a dexamethasone implant for patients with diabetic macular edema. The goal is to see if it improves vision and how well patients tolerate the treatment.

Diabetic Macular Oedema>2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesEndocrinologyOphthalmology

Epcoritamab for Relapsed Large B-Cell Lymphoma

We are studying the effectiveness of Epcoritamab as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma. This trial aims to see how well it works and how safe it is compared to other treatments.

Diffuse Large B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visits No Placebo Standard MedicinesHematologyOncology

Search Clinical Trials in the European Union